Summary of HR 1463: Prohibition on Federal Funding for FDA Rule on Laboratory Developed Tests

Bill Overview

Bill Number: HR 1463

Title: To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.

Status: Introduced in House

Introduced Date: February 21, 2025

Classification: Bill

Purpose and Intent

The primary intent of HR 1463 is to prevent the use of Federal funds for the implementation, administration, or enforcement of a specific final rule issued by the Food and Drug Administration (FDA) concerning Laboratory Developed Tests (LDTs). This rule was published in the Federal Register on May 6, 2024. The bill aims to halt any regulatory actions that could arise from this rule, which may impact the development and use of medical devices and tests created in laboratories.

Key Provisions

• Prohibition of Federal Funding: The bill explicitly states that no Federal funds may be allocated for the implementation, administration, or enforcement of the FDA's final rule on LDTs or any similar regulations.
• Reference to Specific Rule: The bill references the FDA rule published on May 6, 2024 (89 Fed. Reg. 37286), indicating that it targets this particular regulation and any substantially similar future rules.

Affected Parties

• Laboratory Developed Tests (LDTs): The bill primarily affects laboratories that develop and use LDTs, which are tests designed and validated by laboratories for specific patient populations.
• Food and Drug Administration (FDA): The FDA would be directly impacted as the bill restricts its ability to enforce regulations regarding LDTs.
• Healthcare Providers and Patients: Indirectly, healthcare providers and patients may be affected by the availability and regulation of LDTs, which can influence diagnostic and treatment options.

Legislative Actions

• Referred to Committee: On the same day it was introduced, HR 1463 was referred to the House Committee on Energy and Commerce for further consideration.

Sponsors

The bill is sponsored by:
- Brad Finstad (Primary Sponsor)
- August Pfluger (Cosponsor)
- Dan Crenshaw (Cosponsor)
- Neal P. Dunn (Cosponsor)
- Mariannette Miller-Meeks (Cosponsor)
- Andy Barr (Cosponsor)

Conclusion

HR 1463 seeks to limit the FDA's regulatory reach over Laboratory Developed Tests by prohibiting the use of Federal funds for enforcing related rules. This bill reflects ongoing debates about the regulation of medical devices and the balance between innovation in laboratory testing and regulatory oversight. The implications of this bill could significantly impact the landscape of medical testing and diagnostics in the United States.